BioMedNewsBreaks

ThursdaySep 14, 2023 11:33 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports on Plaque Psoriasis Treatment Study

Scinai Immunotherapeutics(NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, is reporting encouraging results from its preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis. According to the report, study results suggest that the NanoAbs, or nanosized VHH antibodies, have potential to relieve symptoms of plaque psoriasis. Currently, there is no safe, affordable biological drug available to treat mild psoriasis, which accounts for 50% of plaque psoriatic patients, has no safe and affordable biological drug available. Scinai’s…

Continue Reading

WednesdaySep 13, 2023 12:54 pm

BioMedNewsBreaks – Aqualab Marks Pivotal Moment with Rebranding, Strategic Reorganization

METER Food today announced its rebranding as Aqualab. The rebranding by the acclaimed pioneer in water activity and moisture content measurement solutions for food and pharma companies marks a pivotal moment in its trajectory. The transformation is part of a strategic reorganization by METER Group, which has consolidated its food-tech and agritech entities under a new holding company, Addium. The transition empowers Aqualab, along with sister companies POMETA and AROYA, to continue rapid expansion while bolstering an overall focus on data intelligence, science, software and sensors. “Aqualab’s journey has been a testament to our dedication to innovation and precision in food production,”…

Continue Reading

WednesdaySep 13, 2023 11:15 am

BioMedNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Announces Acquisition of BlueSky Wellness, Expands Footprint in Global Wellness Market

Lucy Scientific Discovery (NASDAQ: LSDI), a publicly traded company focused on the development, sale, delivery and manufacturing of psychotropic products, is acquiring BlueSky Wellness Inc. and the BlueSky portfolio of brands. According to the announcement, the acquisition adds psychotropic products to the company’s catalog, enabling LSDI to expand its footprint in the global wellness market. BlueSky Wellness brands include Keoni, Keoni Sport, Blush Wellness and AMMA Healing, which have generated more than $20 million in revenue in each of the last two years; BlueSky products range from full-spectrum oils to edible goods, gummies, topicals and beauty products. As part of…

Continue Reading

WednesdaySep 13, 2023 10:18 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Coverage Initiated by Singular Research

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced that Singular Research has initiated analyst coverage on FSD Pharma. The company has not paid for the research report prepared by Singular Research, and all reports on FSD Pharma prepared by analysts represent the views of such analysts and are not necessarily those of FSD Pharma. A copy of the report can be obtained directly from the analyst at Singular Research by contacting BJ…

Continue Reading

TuesdaySep 12, 2023 10:12 am

BioMedNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) to Acquire BlueSky Wellness Inc. in All-Stock Transaction

Lucy Scientific Discovery (NASDAQ: LSDI) is the leader in the psychotropic industry, which recently celebrated the acquisition of the intellectual property of High Times, the most iconic brand in the cannabis industry. Today the company announced an agreement to acquire BlueSky Wellness Inc. and its portfolio of brands, expanding Lucy’s footprint into the growing global wellness category by adding psychotropic products to its capabilities. BlueSky Wellness is a portfolio of plant-based brands including Keoni, Keoni Sport, Blush Wellness and AMMA Healing. It has generated over $20 million in each of the last two years through its e-commerce brands that are…

Continue Reading

MondaySep 11, 2023 2:14 pm

BioMedNewsBreaks – SOHM Inc. (SHMN) Names Seasoned Veteran as VP of Quality

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, has appointment a new vice president of quality. The company announced that Wm. Dewey Rushing will be serving as SOHM vice president for quality. Rushing has been serving on the company’s advisory board member and that experience combined with his impressive background in management and leadership make him ideally qualified for his new role. A well-known expert in the field of pharmaceutical quality validation and cGMP compliance, Rushing has a resume that includes cell therapy IND readiness, quality systems audits, aseptic…

Continue Reading

MondaySep 11, 2023 11:23 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation in H.C. Wainwright, LSX USA Congress 2023 and Upcoming Conferences

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company formerly known as BiondVax Pharmaceuticals Ltd., today announced that its CEO Amir Reichman and Chairman of the Board Mark Germain will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York today and tomorrow (Sept. 11 and 12) and the LSX USA Congress 2023 in Boston this Wednesday and Thursday (Sept. 13 and 14). Investors and potential business partners interested in meeting with Reichman and Germain are invited to contact Scinai investor relations at ir@scinai.com to request a meeting. In addition, members of Scinai’s senior leadership team will be attending…

Continue Reading

MondaySep 11, 2023 10:53 am

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) CEO Releases Stockholder Letter

Longeveron (NASDAQ: LGVN; LGVNR), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, has issued a letter to its stockholders. The letter, from CEO Wa’el Hashad, contains a business update regarding the company’s development of its lead investigational product, Lomecel-B(TM), as well as steps taken to strengthen the board and executive team along with details regarding the current rights offering. The letter noted that Longeveron is involved in ongoing trials of Lomecel-B, a living cell product made from specialized cells isolated from the bone…

Continue Reading

FridaySep 08, 2023 12:09 pm

BioMedNewsBreaks – Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Strengthening Position in Projected $51B Global Cannabis Market

Lucy Scientific Discovery (NASDAQ: LSDI) is featured in a recent FinancialNewsMedia (“FNM”) Editorial. The editorial provides an overview of LSDI’s position in a global cannabis market projected to hit $51 billion this year. According to the press release, the global cannabis market has seen consistent growth year after year, with increasing legalization of cannabis fueling that growth. The release notes that a recent Statista report forecast the global cannabis market to reach $51.27 billion in 2023 with revenue expected to show an annual growth rate (“CAGR”) of 14.95%. For the purposes of the report, the cannabis market was categorized into…

Continue Reading

ThursdaySep 07, 2023 4:57 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced enrollment of 200 of the expected 243 patients in the company’s ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent Glioblastoma Multiforme (“GBM”), an aggressive and incurable form of brain cancer. “As we have noted previously, patient volunteers and their treating clinicians are the backbone of our Berubicin development program. We are deeply sensitive to the fact that these brave patients are facing the battle of their lives and we…

Continue Reading